NASDAQ · ABUS
Healthcare · Biotechnology
$4.77
Up+$0.44 (+9.22%)
Updated Aug 21, 2026, 11:25 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ABUS closed at $4.77 after 21 trading sessions, up 6.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $4.92 | $4.96 | $4.74 | $4.77 | 1.27M |
| Aug 19, 2026 | $4.83 | $5.18 | $4.83 | $4.98 | 3.43M |
| Aug 18, 2026 | $4.79 | $4.85 | $4.645 | $4.84 | 1.45M |
| Aug 17, 2026 | $4.66 | $4.795 | $4.6305 | $4.71 | 1.39M |
| Aug 14, 2026 | $4.60 | $4.71 | $4.55 | $4.67 | 1.44M |
| Aug 13, 2026 | $4.56 | $4.65 | $4.505 | $4.58 | 1.39M |
| Aug 12, 2026 | $4.59 | $4.635 | $4.42 | $4.59 | 1.4M |
| Aug 11, 2026 | $4.60 | $4.72 | $4.60 | $4.67 | 1.05M |
| Aug 10, 2026 | $4.59 | $4.665 | $4.545 | $4.59 | 969.22K |
| Aug 7, 2026 | $4.57 | $4.65 | $4.53 | $4.63 | 796.1K |
| Aug 6, 2026 | $4.57 | $4.64 | $4.45 | $4.54 | 1.27M |
| Aug 5, 2026 | $4.46 | $4.69 | $4.45 | $4.62 | 1.7M |
| Aug 4, 2026 | $4.38 | $4.50 | $4.38 | $4.42 | 958.76K |
| Aug 3, 2026 | $4.34 | $4.425 | $4.31 | $4.36 | 1.42M |
| Jul 31, 2026 | $4.40 | $4.4495 | $4.27 | $4.34 | 1.17M |
| Jul 30, 2026 | $4.30 | $4.42 | $4.26 | $4.41 | 786.24K |
| Jul 29, 2026 | $4.41 | $4.43 | $4.27 | $4.29 | 2.08M |
| Jul 28, 2026 | $4.50 | $4.50 | $4.375 | $4.41 | 633.62K |
| Jul 27, 2026 | $4.41 | $4.525 | $4.40 | $4.41 | 977.8K |
| Jul 24, 2026 | $4.46 | $4.51 | $4.37 | $4.38 | 876.89K |
| Jul 23, 2026 | $4.28 | $4.48 | $4.25 | $4.47 | 1.48M |
The latest Smart Investors Daily articles mentioning ABUS.
ABUS research
Company profile and research snapshot.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 14, 2025 | Chardan Capital | Buy | — |
| Aug 11, 2025 | Chardan Capital | Buy | — |
| Mar 28, 2025 | Chardan Capital | Buy | — |
| Jan 21, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 20, 2024 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 12, 2026
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 400 percent decrease over earnings of $0.01 per share from
Benzinga · Jul 16, 2026
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle ("LNP") technology against Pfizer and BioNTech Received
SeekingAlpha · Jul 13, 2026
Arbutus (ABUS) looks stronger after Moderna validates its LNP patents, with imdusiran showing durable viral control and a solid runwayâread now.
SeekingAlpha · Jun 23, 2026
Moderna, Inc. shifts beyond Covid with mRNA vaccines like mFlusiva, combo shots, and oncology catalysts. Click for more on MRNA stock prospects.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ABUS.
